Last reviewed 2026-05-30 · How we verify

Vaccine Enhancement Patch

Intercell USA, Inc. · Phase 1 active Small molecule ✓ Verified May 2026

Vaccine Enhancement Patch is a Small molecule drug developed by Intercell USA, Inc.. It is currently in Phase 1 development.

The Vaccine Enhancement Patch is a vaccine component that induces an immune response. It is being studied in a clinical trial for the treatment of Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, and Vulvar Diseases.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Vaccine Enhancement Patch
Sponsor	Intercell USA, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vaccine Enhancement Patch CI brief — competitive landscape report
Vaccine Enhancement Patch updates RSS · CI watch RSS
Intercell USA, Inc. portfolio CI

Frequently asked questions about Vaccine Enhancement Patch

What is Vaccine Enhancement Patch?

Vaccine Enhancement Patch is a Small molecule drug developed by Intercell USA, Inc..

Who makes Vaccine Enhancement Patch?

Vaccine Enhancement Patch is developed by Intercell USA, Inc. (see full Intercell USA, Inc. pipeline at /company/intercell-usa-inc).

What development phase is Vaccine Enhancement Patch in?

Vaccine Enhancement Patch is in Phase 1.

Manufacturer: Intercell USA, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing